Exploring strategies for scaling up allogeneic natural killer cell therapy
“...designing a scalable, closed-system manufacturing process from the outset ensures a seamless transition from clinical to commercial scale.”Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Will Rosellini, President, CytoImmune Therapeutics, about the advancements in natural killer (NK) cell therapies for cancer and autoimmune diseases. They also discuss the role of decentralized manufacturing in improving therapy accessibility.
Authors
- Will Rosellini
Institutions
- Aimmune Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Cell and Gene Therapy Insights
- Published
- 2025-05-02
- DOI
- https://doi.org/10.18609/cgti.2025.055
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00